Rituximab: therapeutic benefit! Vitamin R?
Mo
Clifton
C
Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD.
Vire
Berengere
B
Wiestner
Adrian
A
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology* / Q000502:physiology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy; D001402:B-Lymphocytes / Q000187:drug effects; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D000069283:Rituximab